907969-47-5

Usage

General Description

1-(phenylsulfonylacetyl)pyrrolidin-2-one is a chemical compound that belongs to the class of pyrrolidin-2-ones, which are cyclic amides. It is also known by the name Sultopride, and it was originally developed for the treatment of schizophrenia. 1-(phenylsulfonylacetyl)pyrrolidin-2-one contains a phenylsulfonylacetyl group attached to a pyrrolidin-2-one ring, and it is believed to act as a selective dopamine D2 antagonist. It has also been investigated for its potential use in the treatment of other psychiatric disorders and has shown some promise in preclinical studies. However, further research is needed to fully understand its pharmacological properties and potential therapeutic applications.

Upstream product

• 616-45-5 2-pyrrolidinon 
• 72263-17-3 phenylsulfonylacetic acid chloride 
• 103-04-8 (phenylthio)acetic acid 
• 3959-23-7 benzenesulfonylacetic acid 

Downstream Products

• 612065-04-0 trifluoro-methanesulfonic acid 5-oxo-1,2,3,5-tetrahydro-indolizin-6-yl ester 
• 185198-40-7 1-(2-benzenesulfonyl-2-diazoacetyl)pyrrolidin-2-one 
• 253195-64-1 methyl 5-oxo-6-trifluoromethanesulfonyloxy-1,2,3,5-tetrahydroindolizine-8-carboxylate 
• 253195-72-1 methyl-5-oxo-6-phenyl-1,2,3-trihydroindolizine-8-carboxylic acid 
• 253195-68-5 6-hydroxy-2,3-dihydro-1H-indolizin-5-one 
• 13618-93-4 indolizidine 
• 253195-81-2 trifluoromethanesulfonic acid 8-phenylsulfonyl-7-methyl-5-oxo-1,2,3,5-tetrahydroindolizin-6-yl ester 
• 185198-44-1 trifluoromethanesulfonic acid 8-phenylsulfonyl-5-oxo-1,2,3,5-tetrahydroindolizin-6-yl ester 
• 185198-50-9 8-phenylsulfonyl-6-(4-methoxyphenyl)-7-methyl-2,3-dihydro-1H-indolizin-5-one 
• 185198-45-2 8-phenylsulfonyl-6-phenyl-2,3-dihydro-1H-indolizin-5-one 
• 185198-49-6 8-phenylsulfonyl-6-hydroxy-7-methyl-2,3-dihydroi-1H-ndolizin-5-one 
• 185198-43-0 8-(phenylsulfonyl)-6-hydroxy-2,3-dihydro-1H-indolizin-5-one 
• 185198-51-0 6-(4-methoxyphenyl)-7-methyl-2,3-dihydro-1H-indolizin-5-one 

Relevant academic research and scientific papers

PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS

Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders. Disclosed herein is the synthesis of pyridinyl derived therapeutic agents that function as inhibitors of ASK 1 as well as their pharmaceutical compositions and methods of use.

An isomunchnone-based method for the synthesis of highly substituted 2(1H)-pyridones

1-(Benzenesulfonyl-diazoacetyl)-pyrrolidin-2-one was prepared by a diazo transfer of 1-(benzenesulfonylacetyl)-pyrrolidin-2-one with p- acetamidobenzenesulfonyl azide and triethylamine. Treatment of the diazoimide with a catalytic quantity of rhodium(II) acetate resulted in the formation of an isomunchnone dipole, which underwent bimolecular trapping with various dipolarophiles in high yield. The initially formed cycloadducts were not isolable or observed, as they all readily underwent ring opening to give the 3-hydroxy-2(1H)-pyridone ring system. The 3-hydroxy-2(1H)pyridones were readily converted to the corresponding triflates, which function as suitable substrates in various types of palladium-catalyzed cross-coupling reactions. Commercial tetrakis(triphenylphoshine)palladium was found to be a particularly effective catalyst for the cross-coupling with aryl, vinyl, and acetylenic partners. An application of the method to the synthesis of the indolizidine alkaloid (±)-ipalbidine was carried out in eight steps in 17% overall yield. The angiotensin-converting enzyme inhibitor (-)-A58365A was also synthesized by a process based on the [3 + 2]-cycloaddition reaction of a phenylsulfonyl substituted isomunchnone intermediate. The starting material for this process was prepared from L-pyroglutamic acid and involved using a diazo phenylsulfonyl substituted pyrrolidine imide. Treatment of the diazoimide with Rh2(OAc)4 in the presence of methyl vinyl ketone afforded a 3-hydroxy-2-pyridone derivative, which was subsequently converted to the ACE inhibitor in six additional steps.